Option for Synthetic Compounds Clause Samples

Option for Synthetic Compounds. In the event the Option is exercised pursuant to Section 8.2, the Research Fees for each […***…] of the Collaborative Program shall be based on the Steering Committee’s assessment of the […***…] needed to complete […***…] required for Synthetic Compounds for such […***…], provided that there shall be a minimum of […***…] during any […***…]. At each […***…] Steering Committee meeting, the Steering Committee (i) will discuss and agree upon the […***…] for the following […***…] for Synthetic Compounds of research in an effort to complete the Collaborative Program in an expeditious manner as outlined in the Research Plan; and (ii) will forecast […***…] for the next subsequent […***…] for Synthetic Compounds research. In the event the Option is exercised, all work on Natural Compounds will conclude. The […***…] Research Fee shall be calculated by […***…] in any given […***…] by […***…] […***…]. The Research Fees under this Section 7.1 will be paid in equal […***…] installments payable in advance. Payments for any period which is less than […***…] of the Collaborative Period will be prorated based on the actual number of days in such period. Any adjustments in funding due to exercise of the Option above will be made by Firmenich within […***…] of exercise of the Option or with the next […***…] payment, whichever is earlier. These Research Fees are inclusive of […***…]. These payments do not include: (i) […***…] associated with […***…] for the Collaborative Program; or (ii) the […***…] as requested and agreed to by the Steering Committee. Additional Research Fees, if any, may be proposed to the Steering Committee and agreed to in writing. The parties will […***…] all […***…] associated with Natural Compounds (other than for […***…]Senomyx of compound libraries) including, without limitation, […***…], etc. The parties recognize that Firmenich and/or Senomyx may have the in-house capabilities required to perform certain research or development activities associated with Natural Compounds. The Steering Committee will discuss the relative capabilities of the two parties and decide the most appropriate party to perform such activities. Notwithstanding Section 7.1.2 of the Agreement, the parties hereby agree that during the Extension Period, the minimum […***…] shall be […***…]. Unless the Steering Committee intends to approve a greater […***…] for a given […***…], no additional action is required by the Steering Committee to set the level of Research Fees for the Exte...
View Source
Option for Synthetic Compounds. In the event the Option is exercised pursuant to Section 8.2, the Research Fees for each [...***...] of the Collaborative Program shall be based on the Steering Committee’s assessment of the [...***...] needed to complete [...***...] required for Synthetic Compounds for such [...***...], provided that there shall be a minimum of [...***...] during any [...***...]. At each [...***...] Steering Committee meeting, the Steering Committee (i) will discuss and agree upon the [...***...] for the following [...***...] for Synthetic Compounds of research in an effort to complete the Collaborative Program in an expeditious manner as outlined in the Research Plan; and (ii) will forecast [...***...] for the next subsequent [...***...]
View Source

Related to Option for Synthetic Compounds

  • Combination Product The term “

  • For clarity the time allowances provided in clause 2.10 shall operate to reduce the maximum timetabled classroom teaching time specified in clause 4.2 of this agreement.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones) B. Estimated total development time